Financial Daily from THE HINDU group of publications
Tuesday, Mar 16, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Industry & Economy - Health


Ranbaxy gets tentative USFDA nod for hypertension drug

Our Bureau

New Delhi , March 15

RANBAXY Laboratories Ltd has received tentative approval from the US Food and Drug Administration (USFDA), Office of Generic Drugs, to manufacture and market Quinapril Hydrochloride tablets used for the treatment of hypertension.

The tablets would be available in 5 mg, 10 mg, 20 mg and 40 mg units. The total Quinapril Hydrochloride tablet market is estimated to be $632.2 million with Pfizer Pharmaceuticals' Accupril dominating the market with sales of $589 million.

In an official statement, Mr Jim Meehan, Vice-President, Sales and Marketing, Ranbaxy Pharmaceuticals Inc said, "Subject to receiving final FDA approval, we will introduce Quinapril Hydrochloride tablets to further expand our product portfolio of affordable generic alternatives. This product offering in the cardiovascular class of medications will provide benefits to the US healthcare system, prescribers and patients."

Quinapril Hydrochloride could be used alone or in combination with thiazide diuretics.

More Stories on : Announcements | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
BPCL to halve product offtake from Reliance


Ranbaxy gets tentative USFDA nod for hypertension drug
L&T bags Rs 70-cr hotel deal in Bahrain
CAs told to hone up IT skills
RBI nod for $473.21 m ECBs
Nestle: Sales up; but profit growth lukewarm
`Cos must go beyond ethical minimum'
`Cos should adopt corporate governance ratings'
REL to call for gas supply bids for UP power project
Alacrity Housing staff on strike seeking wages
Ludlow Jute Mills may reopen next month
Kochi Refineries signs production pact with BPCL
Marico Industries declares 1:1 bonus
Shareholder files affidavit against L&T-Grasim deal
GM upbeat on Tavera prospects
Zydus plea to allow import of Pekin duck eggs
Getz, Elantra launch plans on track: Hyundai
BHPV chief resigns on `health grounds'



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line